Previous Close | 114.46 |
Open | 114.84 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 114.24 - 115.24 |
52 Week Range | 90.70 - 120.00 |
Volume | |
Avg. Volume | 1,173,134 |
Market Cap | N/A |
Beta (5Y Monthly) | 0.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Skincare company Galderma was on course to raise 2.3 billion ($2.6 billion) Swiss francs from its upcoming initial public (IPO) offering after a positive response from potential investors. The company, whose products includes Cetaphil, a product for damaged and sensitive skin, as well as fillers and skin creams, early on Wednesday announced a price range of 49 to 53 Swiss francs for its flotation - likely to be one of the biggest in Europe this year. The offering consists of up to 40.5 million new shares and 277,000 existing shares, the company said.
Latest surge in world cocoa prices means bad news for Easter egg hunters.
There have been some fears that GLP-1 weight-loss drugs could cause a decline in snack food sales. But European food giant Nestlé (NSRGY, NESN.SW) sees a unique opportunity. CEO Mark Schneider says the company's nutrition products could help those who use medications like Ozempic and Wegovy, who may need foods with additional nutritional benefits. Yahoo Finance's Josh Schafer, Brooke DiPalma, and Pras Subramanian discuss the comments in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich